Meeting
2014 ASCO Annual Meeting
Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel (WP) or eribulin (E) followed by doxorubicin and cyclophosphamide (AC) in women with locally advanced HER2-negative breast cancer (LABC): NSABP FB-9.
Authors
Jame Abraham
Cleveland Clinic, Cleveland, OH
Jame Abraham , Andre Robidoux , Antoinette R. Tan , Marc E. Buyse , Norman Wolmark , Samuel A. Jacobs
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Clinical Trial Registration Number
NCT01705691
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 1058)
DOI
10.1200/jco.2014.32.15_suppl.1058
Abstract #
1058
Poster Bd #
151
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 2 trial of talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer.
First Author: Hatem Hussein Soliman
Poster
2019 ASCO Annual Meeting
Phase II trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer.
First Author: Maryann J. Kwa
Poster
2012 ASCO Annual Meeting
NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC).
First Author: Antoinette R. Tan
Poster
2012 ASCO Annual Meeting
Correlation between miRNA (miR) and gene expression profiles (GEP) and response to neoadjuvant chemotherapy (NT) in patients with locally advanced and inflammatory breast cancer (BC).
First Author: Sierra Mi Li